Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A
J. Clin. Invest. Miho Nozaki, et al. 116:422 doi:10.1172/JCI26316 [Go to this article.]

Figure 6
SPARC regulated VEGF-A effects on CNV. (A) Constitutive (control) RPE/choroid expression of SPARC was decreased 1 day after laser injury and recovered 2 days after injury. Figure is representative of 3 experiments. (B and C) Immunoprecipitation of 3 independent samples revealed that VEGF-A interacted with SPARC (B) but not IGF binding protein-3 (IGFBP-3) (C) in vivo. (D) CNV inhibition by VEGF-A injected 1 day after injury was abolished by recombinant human SPARC (rhSPARC) and restored by neutralizing anti-SPARC Ab (80 pmol). *P < 0.05 compared with PBS. Recombinant SPARC injection alone (white bar) did not change CNV compared with PBS. (E) Neutralizing anti-SPARC Ab (26.7 pmol) but not control mouse IgG abrogated CNV increase induced by VEGF-A 1 day before injury. *P < 0.05 compared with PBS. (F) VEGF-A injected 1 day before laser injury increased CNV in SPARC^+/+ mice but not in SPARC^–/– mice. VEGF-A injected 1 day after laser injury decreased CNV in SPARC^+/+ and SPARC^–/– mice. *P < 0.05 compared with PBS injection on the same day. VEGF-A, 0.1 pmol. n = 10–14 per data point (D–F).